Increases in levels of schistosome-specific immunoglobulin E and CD23 + B cells in a cohort of kenyan children undergoing repeated treatment and reinfection with schistosoma mansoni

Journal of Infectious Diseases

Volumn 202, Issue 3, 2010, Pages 399-405

  Black, Carla L ^a   Muok, Erick M O ^c   Mwinzi, Pauline N M ^c   Carter, Jennifer M ^a   Karanja, Diana M S ^c   Secor, W Evan ^b   Colley, Daniel G ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ARTEMETHER PLUS BENFLUMETOL; CD23 ANTIGEN; IMMUNOGLOBULIN E; PRAZIQUANTEL; ANTHELMINTIC AGENT; HELMINTH ANTIBODY; IMMUNOGLOBULIN E RECEPTOR;

AGE DISTRIBUTION; ANTIBODY SCREENING; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HELMINTH; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPHENOTYPING; KENYA; MAJOR CLINICAL STUDY; MALE; PLASMODIUM FALCIPARUM; PREVALENCE; PRIORITY JOURNAL; REINFECTION; RETREATMENT; SCHISTOSOMA; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SCHOOL CHILD; ANIMAL; BLOOD; CHEMISTRY; IMMUNOLOGY; LONGITUDINAL STUDY; RECURRENT DISEASE; SCHISTOSOMIASIS MANSONI;

ANIMALS; ANTHELMINTICS; ANTIBODIES, HELMINTH; B-LYMPHOCYTES; CHILD; FEMALE; HUMANS; IMMUNOGLOBULIN E; KENYA; LONGITUDINAL STUDIES; MALE; PRAZIQUANTEL; RECEPTORS, IGE; RECURRENCE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI;

EID: 77954734463     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653828     Document Type: Article

References (31)

1. Kabatereine NB, Vennervald BJ, Ouma JH, et al. Adult resistance to schistosomiasis mansoni: age-dependence of reinfection remains constant in communities with diverse exposure patterns. Parasitology 1999; 118:101-105.
2. King CH, Keating CE, Muruka JF, et al. Urinary tract morbidity in schistosomiasis haematobia: associations with age and intensity of infection in an endemic area of Coast Province, Kenya. Am J Trop Med Hyg 1988; 39:361-368.
3. Wilkins HA, Goll PH, Marshall TFD, Moore PJ. Dynamics of Schistosoma haematobium infection in a Gambian community. III. Acquisition and loss of infection. Trans R Soc Trop Med Hyg 1984; 78:227-232.
4. Fulford AJ, Butterworth AE, Ouma JH, Sturrock RF. A statistical approach to schistosome population dynamics and estimation of the life span of Schistosoma mansoni in man. Parasitology 1995; 110(Pt 3):307-316.
5. Warren KS, Mahmoud AAF, Cumming P, Murphy DJ, Houser HB. Schistosomiasis mansoni in Yemeni in California: duration of infection, presence of disease, therapeutic management. Am J Trop Med Hyg 1974; 23:902-909.
6. Woolhouse MEJ, Hagan P. Seeking the ghost of worms past. Nature Med 1999; 5:1225-1227.
7. Karanja DMS, Hightower AW, Colley DG, et al. Resistance to reinfection with Schistosoma mansoni in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study. Lancet 2002; 360:592-596.
8. Dunne DW, Butterworth AE, Fulford AJC, et al. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol 1992; 22:1483-1494.
9. Caldas IR, Correa-Oliveira R, Colosimo E, et al. Susceptibility and resistance to Schistosoma mansoni reinfection: parallel cellular and isotypic immunologic assessment. Am J Trop Med Hyg 2000; 62:57-64.
10. Webster M, Fallon PG, Fulford AJC, et al. Effect of praziquantel and oxamniquine treatment on human isotype responses to Schistosoma mansoni: elevated IgE to adult worm. Parasite Immunol 1997; 19:333-335.
11. Zhaosong Z, Haiwei W, Suchen C, et al. Association between IgE antibody against soluble egg antigen and resistance to reinfection with Schistosoma japonicum. Trans R Soc Trop Med Hyg 1997; 91:606-608.
12. Mwinzi PNM, Ganley-Leal L, Black CL, Secor WE, Karanja DMS, Colley DG. Circulating CD23+ B cell subset correlates with the development of resistance to Schistosoma mansoni reinfection in occupationally exposed adults who have undergone multiple treatments. J Infect Dis 2009; 199:272-279.
13. Suryani S, Fulcher DA, Santner-Nanan B, et al. Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. Blood 2010; 115:519-529.
14. McClosky N, Hunt J, Beavil RL, et al. Soluble CD23 monomers inhibit and oligomers stimulate IgE synthesis in human B cells. J Biol Chem 2007; 282:24083-24091.
15. Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY. CD21 is a ligand for CD23 and regulates IgE production. Nature 1992; 358:505-507. 16. Su TT, Guo B, Wei B, Braun J, Rawlings DJ. Signaling in transitional type 2 B cells is critical for peripheral B-cell development. Immunol Rev 2004; 197:161-178.
16. Su TT, Guo B, Wei B, Braun J, Rawlings DJ. Signaling in transitional type 2 B cells is critical for peripheral B-cell development. Immunol Rev 2004; 197:161-178.
17. Hjelm F, Karlsson MC, Heyman B. A novel B cell-mediated transport of IgE-immune complexes to the follicle of the spleen. J Immunol 2008; 180:6604-6610.
18. Rambert J, Mamani-Matsuda M, Moynet D, et al. Molecular blocking of CD23 supports its role in the pathogenesis of arthritis. PLoS One 2009; 4:e4834.
19. Stief A, Texido G, Sansig G, Eibel H, Le Gros G, van der Putten H. Mice deficient in CD23 reveal its modulatory role in IgE production but no role in T and B cell development. J Immunol 1994; 152:3378-3390.
20. Mutapi F, Ndhlovu PD, Hagan P, Woolhouse MEJ. A comparison of humoral responses to Schistosoma haematobium in areas with low and high levels of infection. Parasite Immunol 1997; 19:255-263.
21. Mutapi F, Ndhlovu PD, Hagan P, et al. Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection. J Infect Dis 1998; 178:289-293.
22. Mutapi F, Hagan P, Woolhouse MEJ, Mduluza T, Ndhlovu PD. Chemotherapy- induced, age-related changes in antischistosome antibody responses. Parasite Immunol 2003; 25:87-97.
23. Handzel T, Karanja DMS, Addiss DG, et al. Geographic distribution of schistosomiasis and soil-transmitted helminthes in western Kenya: implications for antihelminthic treatment. Am J Trop Med Hyg 2003; 69:318-323.
24. Ganley-Leal LM, Mwinzi PN, Cetre-Sossah CB, et al. Correlation between eosinophils and protection against reinfection with Schistosoma mansoni and the effect of human immunodeficiency virus type 1 coinfection in humans. Infect Immun 2006; 74:2169-2176.
25. Gryseels B, Nkulikyinka L, Coosemans MH. Field trials of praziquantel an oxamniquine for the treatment of schistosomiasis mansoni in Burundi. Trans R Soc Trop Med Hyg 1987; 81:641-644.
26. World Health Organization. The control of schistsomiasis.WHOTechnical Report Series 1993; 1-86
27. Black CL, Mwinzi PNM, Muok EMO, et al. Influence of exposure history on the immunology and development of resistance to human schistosomiasis mansoni. PLoS Negl Trop Dis 2010; 4(3):e637.
28. Fujiwara H, Kikutani H, Suematsu S, et al. The absence of IgE antibody- mediated augmentation of immune responses in CD23-deficient mice. Proc Natl Acad Sci U S A 1994; 91:6835-6839.
29. Veneri D, Ortolani R, Franchini M, Tridente G, Pizzolo G, Vella A. Expression of CD27 and CD23 on peripheral blood B lymphocytes in humans of different ages. Blood Transfus 2009; 7:29-34.
30. Erkeller-Yuksel FM, Deneys V, Yuksel B, et al. Age-related changes in human blood lymphocyte populations. J Pediatr 1992; 120:216-222.
31. Odogwu SE, Ramamurthy NK, Kabatereine NB, et al. Schistosoma mansoni in infants (aged <3 years) along the Ugandan shoreline of Lake Victoria. Ann Trop Med Parasitol 2006; 100:315-326.